Decision Criterion and Value of Information Analysis: Optimal Aspirin Dosage for Secondary Prevention of Cardiovascular Events

被引:10
|
作者
Basu, Anirban [1 ,2 ,3 ]
Meltzer, David [4 ,5 ]
机构
[1] Univ Washington, Dept Pharm, Comparat Hlth Outcome Policy & Econ CHOICE Inst, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA
[2] Univ Washington, Dept Hlth Serv, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA
[3] Univ Washington, Dept Econ, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA
[4] Univ Chicago, Dept Med, Harris Sch Publ Policy Studies, Sect Hosp Med, 5841 S Maryland Ave, Chicago, IL 60637 USA
[5] Univ Chicago, Dept Econ, Chicago, IL 60637 USA
关键词
aspirin; cardiovascular; decision criterion; value of information; ACUTE MYOCARDIAL-INFARCTION; COLLABORATIVE METAANALYSIS; IMPLEMENTATION; DISEASE;
D O I
10.1177/0272989X17746988
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background. In value of information (VOI) calculations, such as the expected value of perfect information (EVPI), partial perfect information (EVPPI), sample information (EVSI) or implementation (EVIM), the maximum expected value criterion defines the decision making criterion for the adoption of decisions for treatments. However, because decision makers are often risk averse, the uncertainty that accompanies a decision problem may influence adoption decisions. Methods. VOI estimates were studied based on 2 alternate decision making criteria: 1) maximum expected value and 2) 95% credible intervals. These criteria were applied to a probabilistic minimal lifetime model of incident cardiovascular events and mortality among target patients comparing 2 daily doses of aspirin (81 mg and 325 mg). Model parameters were based on literature reviews and data analyses. Results. Expected life-years under 81 v. 325 mg of aspirin were estimated to be 14.86 (SE, 0.10) and 14.72 (0.31) respectively, with a difference of 0.14 (0.29). The probability that 81 mg was optimal was estimated to be 67%. Under Decision Criterion 1, EVIM and EVPI were about 233-thousand and 411-thousand years, respectively. Under Criterion 2, EVIM was undefined, as there remains ambiguity about what to implement. Consequently, EVPI becomes the entire 644-thousand years. Also, under Criterion 1, EVSI reaches an asymptote at a sample size of 10,000 per arm, with minimal gains in value beyond a 5,000 person per arm trial. With Criterion 2, a sample size of 10,000 per arm or higher is substantially more valuable than lower sample sizes. Conclusion. Alternative decision criteria for treatment adoption change the VOI. Decision criteria should be justified for VOI analyses. If multiple criteria may be relevant, analysts should complete VOI estimates using multiple criteria.
引用
收藏
页码:427 / 438
页数:12
相关论文
共 50 条
  • [1] Aspirin or clopidogrel for secondary prevention of cardiovascular events: Is there a winner?
    Gaspoz, JM
    de Moerloose, P
    AMERICAN JOURNAL OF MEDICINE, 2004, 116 (12): : 850 - 852
  • [2] Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events
    Joonseok Kim
    Richard C. Becker
    Journal of Thrombosis and Thrombolysis, 2016, 41 : 493 - 504
  • [3] Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events
    Kim, Joonseok
    Becker, Richard C.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 41 (03) : 493 - 504
  • [4] Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1561): : 196 - 197
  • [5] Aspirin in prevention of cardiovascular events
    Jaeschke, Roman
    Guyatt, Gordon
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (11): : 909 - 909
  • [6] Aspirin for the Prevention of Cardiovascular Events
    Lee, Cheol Whan
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2006, 49 (02): : 181 - 186
  • [7] Aspirin for prevention of cardiovascular events
    Hiatt, William R.
    BRITISH MEDICAL JOURNAL, 2008, 337
  • [8] Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
    Djatche L.M.
    Varga S.
    Lieberthal R.D.
    PharmacoEconomics - Open, 2018, 2 (4) : 371 - 380
  • [9] Underuse of Aspirin for Primary and Secondary Prevention of Cardiovascular Disease Events in Women
    Rivera, Cathleen M.
    Song, Juhee
    Copeland, Laurel
    Buirge, Chris
    Ory, Marcia
    McNeal, Catherine J.
    JOURNAL OF WOMENS HEALTH, 2012, 21 (04) : 379 - 387
  • [10] Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
    Zhao, Binghao
    Wu, Qian
    Wang, Li
    Liao, Chen
    Dong, Yifei
    Xu, Jingsong
    Wei, Yiping
    Zhang, Wenxiong
    FRONTIERS IN PHARMACOLOGY, 2021, 11